TY - JOUR
T1 - Quantifying the public's view on social value judgments in vaccine decision-making
T2 - A discrete choice experiment
AU - Luyten, Jeroen
AU - Kessels, Roselinde
AU - Atkins, Katherine E.
AU - Jit, Mark
AU - van Hoek, Albert Jan
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/5
Y1 - 2019/5
N2 - Vaccination programs generate direct protection, herd protection and, occasionally, side effects, distributed over different age groups. This study elicits the general public's view on how to balance these outcomes in funding decisions for vaccines. We performed an optimal design discrete choice experiment with partial profiles in a representative sample (N = 1499) of the population in the United Kingdom in November 2016. Using a panel mixed logit model, we quantified, for four different types of infectious disease, the importance of a person's age during disease, how disease was prevented—via direct vaccine protection or herd protection—and whether the vaccine induced side effects. Our study shows clear patterns in how the public values vaccination programs. These diverge from the assumptions made in public health and cost-effectiveness models that inform decision-making. We found that side effects and infections in newborns and children were of primary importance to the perceived value of a vaccination program. Averting side effects was, in any age group, weighted three times as important as preventing an identical natural infection in a child whereas the latter was weighted six times as important as preventing the same infection in elderly aged 65–75 years. These findings were independent of the length or severity of the disease, and were robust across respondents’ backgrounds. We summarize these patterns in a set of preference weights that can be incorporated into future models. Although the normative significance of these weights remains a matter open for debate, our study can, hopefully, contribute to the evaluation of vaccination programs beyond cost-effectiveness.
AB - Vaccination programs generate direct protection, herd protection and, occasionally, side effects, distributed over different age groups. This study elicits the general public's view on how to balance these outcomes in funding decisions for vaccines. We performed an optimal design discrete choice experiment with partial profiles in a representative sample (N = 1499) of the population in the United Kingdom in November 2016. Using a panel mixed logit model, we quantified, for four different types of infectious disease, the importance of a person's age during disease, how disease was prevented—via direct vaccine protection or herd protection—and whether the vaccine induced side effects. Our study shows clear patterns in how the public values vaccination programs. These diverge from the assumptions made in public health and cost-effectiveness models that inform decision-making. We found that side effects and infections in newborns and children were of primary importance to the perceived value of a vaccination program. Averting side effects was, in any age group, weighted three times as important as preventing an identical natural infection in a child whereas the latter was weighted six times as important as preventing the same infection in elderly aged 65–75 years. These findings were independent of the length or severity of the disease, and were robust across respondents’ backgrounds. We summarize these patterns in a set of preference weights that can be incorporated into future models. Although the normative significance of these weights remains a matter open for debate, our study can, hopefully, contribute to the evaluation of vaccination programs beyond cost-effectiveness.
KW - Age
KW - Cost-effectiveness analysis
KW - Decision making
KW - Equity
KW - Herd immunity
KW - Priority-setting
KW - Side effects
KW - United Kingdom
UR - http://www.scopus.com/inward/record.url?scp=85063318259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063318259&partnerID=8YFLogxK
U2 - 10.1016/j.socscimed.2019.03.025
DO - 10.1016/j.socscimed.2019.03.025
M3 - Article
C2 - 30925392
AN - SCOPUS:85063318259
SN - 0277-9536
VL - 228
SP - 181
EP - 193
JO - Social Science and Medicine
JF - Social Science and Medicine
ER -